Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers?HomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers?Simply Wall StSimply Wall St.January 3, 2020ReblogShareTweetShareView photosAllen Baharaff has been the CEO of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) since 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels. See our latest analysis for Galmed Pharmaceuticals How Does Allen Baharaff's Compensation Compare With Similar Sized Companies?At the time of writing, our data says that Galmed Pharmaceuticals Ltd. has a market cap of US$123m, and reported total annual CEO compensation of US$1.5m for the year to December 2018. While we always look at total compensation first, we note that the salary component is less, at US$384k. We note that more than half of the total compensation is not the salary; and performance requirements may apply to this non-salary portion. We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$522k.As you can see, Allen Baharaff is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Galmed Pharmaceuticals Ltd. is paying too much. We can get a better idea of how generous the pay is by looking at the performance of the underlying business.You can see a visual representation of the CEO compensation at Galmed Pharmaceuticals, below.NasdaqCM:GLMD CEO Compensation, January 3rd 2020MoreIs Galmed Pharmaceuticals Ltd. Growing?Over the last three years Galmed Pharmaceuticals Ltd. has grown its earnings per share (EPS) by an average of 34% per year (using a line of best fit). It has seen most of its revenue evaporate over the past year.This demonstrates that the company has been improving recently. A good result. Revenue growth is a real positive for growth, but ultimately profits are more important. Shareholders might be interested in this free visualization of analyst forecasts.Has Galmed Pharmaceuticals Ltd. Been A Good Investment?Boasting a total shareholder return of 43% over three years, Galmed Pharmaceuticals Ltd. has done well by shareholders. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.In Summary...We examined the amount Galmed Pharmaceuticals Ltd. pays its CEO, and compared it to the amount paid by similar sized companies. Our data suggests that it pays above the median CEO pay within that group.However we must not forget that the EPS growth has been very strong over three years. On top of that, in the same period, returns to shareholders have been great. So, considering this good performance, the CEO compensation may be quite appropriate. If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Galmed Pharmaceuticals.Important note: Galmed Pharmaceuticals may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt. If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHere are 5 reasons the stock market is having its worst decline since 2008, and only one of them is the coronavirusMarketWatchDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoOil’s Worst Week Since 2014 Puts Pressure on OPEC+ to RespondBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance